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Expression analysis of the osteoarthritis
genetic susceptibility locus mapping to an
intron of the MCF2L gene and marked by
the polymorphism rs11842874
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Abstract
Background: Osteoarthritis (OA) is a painful, debilitating disease characterised by loss of articular cartilage with
concurrent changes in other tissues of the synovial joint. Genetic association studies have shown that a number of
common variants increase the risk of developing OA. Investigating their activity can uncover novel causal pathways
and potentially highlight new treatment targets. One of the reported OA association signals is marked by the single
nucleotide polymorphism (SNP) rs11842874 at chromosome 13q34. rs11842874 is positioned within a small linkage
disequilibrium (LD) block within intron 4 of MCF2L, a gene encoding guanine-nucleotide exchange factor DBS.
There are no non-synonymous SNPs that correlate with this association signal and we therefore set out to assess
whether its effect on OA susceptibility is mediated by alteration of MCF2L expression.
Methods: Nucleic acid was extracted from cartilage, synovial membrane or infrapatellar fat pad tissues from OA
patients. Expression of MCF2L was measured by quantitative PCR and RNA-sequencing whilst the presence of DBS
was studied using immunohistochemistry. The functional effect of SNPs within the 13q34 locus was assessed using
public databases and in vitro using luciferase reporter analysis.
Results: MCF2L gene and protein expression are detectable in joint tissues, with quantitative differences in the
expression of the gene and in the transcript isoforms expressed between the tissues tested. There is an expression
quantitative trait locus (eQTL) operating within synovial membrane tissue, with possession of the risk-conferring A
allele of rs11842874 correlating with increased MCF2L expression. SNPs within the rs11842874 LD block reside
within transcriptional regulatory elements and their direct analysis reveals that several show quantitative differences
in regulatory activity at the allelic level.
Conclusions: MCF2L is subject to a cis-acting eQTL in synovial membrane that correlates with the OA association
signal. This signal contains several functional SNPs that could account for the susceptibility and which therefore
merit further investigation. As far as we are aware, this is the first example of an OA susceptibility locus operating
as an eQTL in synovial membrane tissue but not in cartilage.
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Background
Osteoarthritis (OA) is an age-associated disease charac-
terised by the loss of articular cartilage in synovial joints
and is multifactorial in its onset. There are currently no
pharmacological interventions for patients with OA:
total joint replacement is the only effective treatment of
end-stage disease but is relatively costly and highly inva-
sive. With the global population increasing in size and in
age, and with the incidence of obesity rising, OA is a
growing burden on public health budgets. It would be par-
ticularly beneficial, therefore, to identify novel therapeutic
targets within OA pathways to improve patient outcomes.
While environmental factors can impact upon OA
disease progression, it is now clear that genetic factors
contribute significantly to the risk of developing OA.
Candidate gene and genome-wide association studies
(GWAS) have so far identified 16 novel OA risk loci
across various joint sites and populations (reviewed in
[1] and [2]). These variants are common within the
population and have typically small effect sizes that
together contribute a significant risk towards develop-
ing OA.
During the last decade, it has become apparent that
most alleles influencing polygenic traits do so by modu-
lating gene expression, so called expression quantitative
trait loci or eQTLs. There are several examples of eQTLs
in OA, including those acting on the susceptibility genes
GDF5, DIO2 and ALDH1A2 [3–6].
The majority of OA risk loci do not encompass genes
for which there is previously defined mechanistic links
to joint development or maintenance. Investigating their
role in OA pathology is therefore of significant interest
to uncover novel causal pathways and new therapeutic
targets. One such risk locus was identified following a
GWAS and subsequent meta-analysis of over 19,000 OA
cases and 24,500 controls and involved the study of
directly typed and imputed single nucleotide polymor-
phisms (SNPs) [7]. This signal is positioned within
MCF2L on chromosome 13q34 and is marked by
rs11842874. This A/G single nucleotide polymorphism
(SNP) has a minor allele frequency (MAF) of 7 % in
Europeans and generated an odds ratio (OR) in hip and
knee OA of 1.17 for the major, risk-conferring A allele
(p = 2.1 × 10−8).
This signal spans a 13 kb interval of intron 4 of the
gene, with rs11842874 having an r2 > 0.8 with only six
other SNPs within this small linkage disequilibrium (LD)
block. MCF2L encodes the cytosolic guanine nucleotide
exchange factor DBS, known to co-localise and interact
with signalling proteins RhoA, Cdc42 and Rac1 [8–15].
These proteins are central to chondrocyte development
and hypertrophy whilst Rac1 also mediates the invasive
properties of fibroblast-like synoviocytes in rheumatoid
arthritis. None of the genes that flank MCF2L are
stronger OA candidates than this gene. Based on these
observations, MCF2L itself is the most likely candidate
gene, with none of the surrounding genes having known
roles in the musculoskeletal system.
The focus of our study therefore was to characterise
MCF2L gene and protein expression in joint tissues and
to determine whether an eQTL is operating on the gene
that correlates with genotype at the association SNP. We
also directly assessed the functionality of the seven
highly correlated SNPs within the 13 kb LD block.
Methods
Patients
Cartilage was obtained from patients undergoing elective
total knee or hip replacement surgery due to primary
OA. Cartilage was also collected from patients who had
undergone a hip replacement due to a neck-of-femur
(NOF) fracture. The cartilage of the OA patients had
visible lesions and these patients were screened to ex-
clude OA due to trauma or other pathologies. The NOF
patients showed no signs or symptoms of hip OA, with
the cartilage being macroscopically intact and with no
lesions. The cartilage was collected from the tibial plat-
eau and the lateral and medial femoral condyles. For the
OA patients, the cartilage was collected at sites distal to
the OA lesion. Synovium and infrapatellar fat pad were
also collected from knee OA patients. The Newcastle
and North Tyneside research ethics committee granted
ethical approval for the collection of tissue (REC reference
number 09/H0906/72) and verbal and written informed
consent for its use and the publication of subsequent data
was obtained from each donor. Patients were recruited by
The Newcastle upon Tyne Hospitals NHS Foundation
Trust, encompassing the Royal Victoria Infirmary and the
Freeman Hospital. Patients were recruited by The
Newcastle upon Tyne Hospitals NHS Foundation
Trust, encompassing the Royal Victoria Infirmary and the
Freeman Hospital. Patients were assigned an anonymised
Patient ID prior to laboratory members being granted
access to their data. We have allocated them another
anonymised Patient number to further prevent the identi-
fication of individuals that have been included in this
study. Details regarding these patients can be found in
Additional file 1.
Nucleic acid extraction
Tissue specimens were snap-frozen at −80 °C and ground
to a powder whilst frozen with liquid nitrogen. For cartil-
age, DNA and RNA were extracted using TRIzol reagent
(Life Technologies, UK) as per the manufacturer’s proto-
col, with the upper aqueous phase separated for RNA
isolation, while the interphase and lower organic phase
were used to isolate DNA. For synovium and fat pad,
DNA and RNA were extracted using the E.Z.N.A. DNA/
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RNA isolation kit (Omega Biotek, VWR, UK) as per the
manufacturer’s instructions.
Quantitative gene expression analysis
cDNA was synthesised from 1 μg of total RNA using the
First Strand synthesis system (Invitrogen, UK) after an
initial 30 min treatment with 1 unit of Turbo DNase
(Ambion, UK) at 37 °C. Relative gene expression was
measured by quantitative PCR using TaqMan® chemistry
and reagents. Predesigned TaqMan® assays were used to
quantify expression of MCF2L (Applied Biosystems, UK)
and three housekeeping genes: HPRT1, 18S and GAPDH
(Integrated DNA Technologies, UK), as described pre-
viously [16]. Reactions were performed in triplicate
on an ABI PRISM 7900HT Sequence Detection System
(Applied Biosystems, UK) and relative MCF2L gene ex-
pression was calculated by the 2-ΔCt method, where ΔCt is
the mean Ct value of the three housekeeping genes
subtracted from the Ct value of MCF2L. Outliers were
removed from the analysis by Grubbs’ test and statis-
tical analysis was performed using the non-parametric
Kruskal-Wallis test for analysis between three groups,
or the non-parametric Mann–Whitney U test for ana-
lysis between two groups.
RNA sequencing (RNA-seq) analysis
For chondrocytes, briefly, total RNA was extracted from
the cartilage of 10 hip OA and 6 NOF patients and
subjected to 78-base paired-end sequencing using an
Illumina Genome Analyser IIx according to the manu-
facturer’s protocol (these 16 patients are independent of
those used in the above quantitative PCR analysis). Se-
quencing reads were filtered to trim low quality ends be-
fore aligning them to known human genome transcript
sequences using Salmon, a rapid transcriptome quantifi-
cation tool and successor to Sailfish [17], which utilized
an index based on Ensembl GRCh38 [18]. Bioconductor
package cqn was used to normalise read counts and
minimise bias due to gene length and GC content. For
fibroblast-like synoviocytes and synovial macrophages,
publically available RNA-seq raw data in the fastq
format was downloaded from the publically available
European Nucleotide Archive (ENA; http://www.ebi.ac.uk/
ena) for accession numbers SRX105525, SRX105526,
SRX544934 and SRX544936. No permissions were re-
quired. All samples were QC checked using fastqc (http://
www.bioinformatics.babraham.ac.uk/projects/fastqc/) with
no trimming. Quantification was performed using Salmon
and GRCh38. Fragments per kb of exon per million reads
mapped (FPKM) values for transcript variants of the target
gene, and an aggregated gene level, were extracted
using R (http://www.R-project.org/) and visualized
using the ggplot2 library (http://ggplot2.org).
Immunohistochemistry
Tissue was fixed for 24 h at 4 °C in 4 % paraformalde-
hyde. Sections were de-waxed in xylene and rehydrated
through graded ethanol (100–50 %) and washed in
distilled water. Slides were placed into a 2100 Retriever
(Aptum Biologics, UK) filled with 10 mM citric acid
buffer, pH 6 and processed as per the manufacturer’s
protocol. Slides were then rinsed 3 times with deionised
water including a final 15 min wash. Sections were
washed in TBS (20 mM Tris, pH 7.4 containing 0.9 %
NaCl) with agitation for 5 min then incubated in TBS
containing 0.3 % hydrogen peroxide to quench endogen-
ous peroxidase activity. Sections were washed in TBS
with agitation for 5 min and incubated in 2.5 % horse
blocking serum (Vector Laboratories) for 20 min. Excess
serum was removed before incubating for 30 min in the
presence or absence of an α-DBS antibody (1:350 dilution;
Atlas Antibodies, HPA008614). Sections were washed in
TBS for 5 min before incubating with ImmPRESS™
(Peroxidase) Polymer Anti-Rabbit Ig Reagent (Vector
Laboratories) for 30 min. A further 5 min wash step in
TBS was carried out before incubating with 3,3′-diamino-
benzidine (Peroxidase (HRP) Substrate Kit, Vector La-
boratories) for 5 min. Sections were washed in water for
5 min then counterstained in Mayer’s haematoxylin (Leica
Biosystems) for 30 s. Sections were washed in water for
1 min then developed in Scott’s water (20 g/l sodium
bicarbonate, 3.5 g/l magnesium sulphate), washed exten-
sively in water for 2 min and dehydrated through ethanol
as above, cleared in xylene and mounted in DPX (Sigma
Aldrich). Sections were visualised using a DM4000B
microscope (Leica).
Genotyping
Genotyping was performed by pyrosequencing using
PyroMark24 (Qiagen, UK) as per the manufacturer’s
instructions. The sequence encompassing rs11842874
was PCR amplified using the following primers in a 20 μl
reaction volume: biotinylated forward primer 5ʹ-Btn-GA
CAAAATTCAACGGCAG-3ʹ and reverse primer 5ʹ-TG
AGTGACGGCAGCGAGT-3ʹ. Samples were analysed on
the PyroMark Q24 MDx platform (Qiagen GmbH,
Nordrhein-Westfallen, Germany) using the sequencing
primer 5ʹ-GCCCCATCCCGACTC-3ʹ (Sigma-Aldrich)
and the PyroMark Gold Q96 reagents Kit, following
manufacturer’s instructions. Sequences were generated
automatically and an output of allelic ratio produced using
PSQ 96 SQA software (Qiagen).
Online database searches
The Broad Institute [19] online software was used to
search for SNPs in high LD (r2 > 0.8) with rs11842874
whilst the RegulomeDB [20] online database was used to
explore the functionality of the polymorphisms. The
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GTEx portal [21] online database was used to explore
eQTL data (www.gtexportal.org).
Cloning and luciferase reporter assays
DNA fragments containing each allele of each SNP were
amplified by PCR from patient DNA with primers
containing restriction sites for MluI (ACGCGT) and
XhoI (CTCGAG) (Additional file 2). PCR products and
pGL3-promoter vector (Promega) were digested using
MluI and XhoI (New England Biolabs) as per the manu-
facturer’s protocol. Linearised vector and PCR products
were then gel purified after agarose electrophoresis using
QIAquick gel extraction kit (Qiagen). Ligations were
performed using T4 ligase (New England Biolabs) as per
the manufacturer’s protocol. Mach1 competent cells
(Invitrogen) were used to amplify the ligated products
and DNA was purified using PureYield plasmid miniprep
or maxiprep systems (Promega). Incorporation of the
correct sequence was confirmed by sequencing each al-
lele of each SNP. For the luciferase reporter assay, the
human liposarcoma cell line SW872 and the human
osteosarcoma cell line U2OS were used. Cells were
seeded at 10,000 cells per well in 96 well plates. Twenty
four hours later cells were transfected with 50 ng of
vector construct as well as 6 ng of a renilla luciferase
control vector (pRL-TK, Promega), using FugeneHD
transfection reagent (Promega). Cells were incubated for
a further 24 h then lysed and luciferase and renilla read-
ings measured using the Dual-luciferase reporter assay
system (Promega) as per the manufacturer’s instructions.
Values were recorded using a MicroLumat Plus LB96V
luminometer (Berthold Technologies UK, Harpenden,
UK). A minimum of six independent experiments
were performed with six wells transfected per con-
struct and statistical analysis was carried out using
the Mann–Whitney U test.
Results
Characterisation of MCF2L gene, transcript and protein
expression in primary joint tissues and cells
MCF2L gene expression has not been described previ-
ously in OA-related joint tissues. We therefore initially
characterised expression of the gene in three major joint
tissues that are readily available to us via joint surgery:
cartilage, synovium and fat pad. Quantitative PCR
analysis revealed that MCF2L expression was highest in
fat pad (n = 65), followed by synovium (n = 93), with
comparatively lower levels in cartilage (n = 77; hip and
knee cartilage samples) (Fig. 1a). A non-parametric
Kruskal-Wallis analysis reveals that the differences in
expression between these three tissue types are highly
significant. We next compared MCF2L expression levels
between OA and non-OA (NOF) cartilage by quantita-
tive PCR and by RNA-seq analysis. For the qPCR
analysis, MCF2L expression was found to be 1.7-fold
higher in NOF cartilage (Fig. 1b, p = 0.027). For the
RNA-seq analysis, involving an independent panel of
OA hip and NOF patients, MCF2L expression was again
found to be higher in the NOF patients, this time by
1.5-fold (Fig. 1c, p = 0.042).
We further analysed our RNA-seq data to determine
which of the 21 MCF2L protein coding transcript iso-
forms predicted by Ensembl (http://www.ensembl.org/
index.html; Additional file 3) are expressed in cartilage.
We found that five protein coding transcript isoforms
were expressed at a fragments per kilobase of transcript
per million mapped reads (FPKM) threshold of >1
(Fig. 1d), with no differences in expression between OA
and NOF. We also analysed RNA-seq data obtained via
the publicly available Sequence Reads Archive (SRA)
at NCBI (http://www.ncbi.nlm.nih.gov/sra/) to assess
MCF2L isoform expression in the two main cell types
within healthy synovium tissue: fibroblast-like synovio-
cytes (FLS) and macrophages. Data from two FLS samples
(accession numbers SRX105525 and SRX105526) revealed
that ten of the 21 protein-coding transcript isoforms are
expressed (FPKM >1) with a high degree of variability in
overall gene and isoform expression between the two sam-
ples (Fig. 1e). All of the five transcript isoforms expressed
in cartilage tissue were also found in one or both of the
FLS samples. In synovial macrophages co-cultured with
FLS (accession number SRX544934), the FPKM describ-
ing overall MCF2L gene expression (‘MCF2L gene’) was
below 1 thus no isoforms were detected above this level
(Fig. 1f). In synovial macrophages co-cultured with FLS in
the presence of 20 ng/μl tumour necrosis factor (TNF)
(accession number SRX544936), two transcript isoforms
were expressed at FPKM >1 (Fig. 1g).
In summary, we note that between chondrocytes, syn-
ovial macrophages and synovial fibroblasts, a total of 11
transcript isoforms were expressed. Isoform MCF2L-003
was the only one expressed in chondrocytes, fibroblast-like
synoviocytes and macrophages co-cultured with FLS and
TNF; the remaining ten isoforms were expressed in a max-
imum of two of the three cell types tested. We were unable
to directly compare overall gene or isoform expression be-
tween cell types as these were separate experiments. The
conclusions drawn from these data should be interpreted
with caution as the n number used for the synovial fibro-
blasts and macrophage data are extremely low. We were
unable to analyse adipocyte RNA-seq data due to a lack of
suitable publically available data.
In addition to these analyses, we performed immunohis-
tochemistry on cartilage, synovium and fat pad from OA
patients with an α-DBS (the protein product of MCF2L)
primary antibody, and compared staining to that found in
tonsil tissue as a positive control (Additional file 4). DBS
protein was detectable in chondrocytes, synovial fibroblasts,
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Fig. 1 (See legend on next page.)
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synovial macrophages and adipocytes. Comparatively dark
staining was seen around the plasma membrane and within
the cytosol in tonsil lymphocytes. Staining was less intense
in the joint tissue cells and was more evenly distributed
throughout the cytosol, with less concentrated staining
around the plasma membrane.
In summary, MCF2L is expressed in the three joint
tissues that we analysed but with quantitative differences
between the tissues and in the relative abundance of
MCF2L transcript isoforms.
Quantitative MCF2L expression in cartilage, synovium
and fat pad stratified by genotype at the OA-risk locus
rs11842874
Having shown that MCF2L is expressed at the gene and
protein level in the joint tissues, we next assessed
whether an eQTL was operating at the rs11842874 locus
in one or more of these tissues. Having measured
MCF2L expression in OA cartilage, fat pad and syno-
vium tissue (Fig. 1a), we then genotyped the same indi-
viduals at rs11842874 and stratified MCF2L expression
by genotype at this SNP. Since the MAF of rs11842874
is low (7 % in Europeans), major allele homozygotes
(AA) were compared to minor allele carriers (AG and GG
combined) to ensure sufficient power in our statistical
analyses. Of the 77 cartilage samples analysed in Fig. 1a,
75 were genotyped whilst all 65 of the fat pad samples and
all 93 of the synovium samples were genotyped.
In cartilage and fat pad, we found no significant differ-
ence in MCF2L gene expression between the two geno-
types (Fig. 2, p > 0.05). In synovium tissue however,
MCF2L expression was significantly higher in major allele
homozygotes (p = 0.0487). We stratified gene expression
by sex and joint for each tissue type but saw no sex-
specific or joint-specific correlations (data not shown).
There is evidence, therefore, of an eQTL at this locus that
correlates with the OA-association signal, with possession
of the risk-conferring A allele correlating with increased
MCF2L expression in OA synovium tissue.
In addition to our own eQTL analysis, we carried out a
search of the GTEx project online database. This database
contains data relating to tissue specific eQTLs described
in a variety of tissue types. Unfortunately, for the purpose
of this study, the project does not currently contain
data relating to our tissue types of interest. Neverthe-
less, MCF2L is subject to an eQTL in skeletal muscle
(p < 0.003) and oesophagus muscularis (p < 0.0003).
However, the regulatory SNPs driving this eQTL are
in a region of MCF2L that has low LD (r2 ≤ 0.1) with
rs11842874 (Additional file 5).
Due to the low MAF of rs11842874 and the absence of
MCF2L transcript SNPs in LD with this intronic SNP,
which precluded our identification of a testable number
of compound heterozygotes, we were unable to directly
test allelic expression of MCF2L by allelic expression
imbalance (AEI) analysis (also known as differential
allelic expression (DAE); [4, 16]). Furthermore, we were
unable to successfully design reliable assays for the
limited number of suitable MCF2L transcript SNPs that
exist for this gene.
The rs11842874 LD block is functional
The OA risk locus is narrow and contains rs11842874
and only six SNPs that have an r2 > 0.8 with this index
SNP (Table 1); all reside within intron 3 of MCF2L with
reference to transcript isoforms MCF2L-002 and MCF2L-
201 (Fig. 3a). An analysis of online public databases re-
vealed that this region is predicted to have transcriptional
regulatory activity, as summarised in Additional file 6.
Each of the 7 SNPs resides within a domain correlat-
ing with either weak transcriptional activity or strong
enhancer effects.
We used a luciferase dual-reporter assay system to
directly investigate the functionality of each allele of
each of the seven SNPs. DNA surrounding each SNP
was cloned separately into a luciferase reporter construct
and constructs were created for both alleles. For
rs118021693, one region of 772 bp (rs118021693 (A))
(See figure on previous page.)
Fig. 1 Analysis of relative MCF2L expression and of its protein coding transcript isoforms. a MCF2L expression measured by qPCR in cartilage,
synovium and fat pad from OA patient donors. MCF2L expression was plotted relative to three housekeeping genes (GAPDH, 18S and HPRT1)
using the 2-ΔCt method. Each dot represents an individual sample. Lines represent the mean value of expression and the standard error of the
mean. The p value was calculated using a non-parametric Kruskal-Wallis test to highlight the differences in mean expression levels between each
of the three tissue types tested. b MCF2L expression measured by qPCR in OA hip and NOF. Horizontal lines represent the mean and standard
error of the mean. c MCF2L expression in OA hip and NOF cartilage as measured by RNA-seq. Expression is measured as fragments per kilobase of exon
per million fragments mapped (FPKM). Horizontal lines represent the mean and standard error of the mean. For b and c, statistical significance was
assessed using the Mann–Whitney U test and is not corrected for multiple testing. d MCF2L protein-coding transcript isoform expression as measured
by RNA-seq in the OA hip (grey bars) and NOF cartilage (black bars) samples used in c. e Publically available MCF2L protein-coding transcript isoform
expression as measured by RNA-seq in two fibroblast-like synoviocyte (FLS) samples: SRX105525, shown as black filled bars, and SRX105526, shown as
grey filled bars. f Publically available MCF2L protein-coding transcript isoform expression as measured by RNA-seq in synovial macrophages co-cultured
with FLS. g Publically available MCF2L protein-coding transcript isoform expression as measured by RNA-seq in synovial macrophages co-cultured with
FLS in the presence of tumour necrosis factor (TNF). For d-g, the isoforms are labelled with their Ensembl ID on the x-axis and are in the order listed in
Additional file 3. Their relative expression, measured as FPKM, is on the y-axis. ‘MCF2L gene’ represents the aggregated expression level of all isoforms
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was cloned and one region of 1216 bp (rs118021693 (B))
was cloned; the larger insert incorporated a region with
predicted insulator activity. To select an appropriate hu-
man cell line for transfection, we tested a variety of lines
for expression of MCF2L (data not shown). Most did
not express the gene (this included transformed synovial
fibroblasts) or expressed it at a low level. We settled on
two cells lines that did express the gene and which
would therefore be synthesising transcriptional proteins
regulating MCF2L expression: the liposarcoma cell line
SW872 and the osteosarcoma cell line U2OS. Both are
of mesenchymal stem cell origin and as such are devel-
opmentally related to the primary joint tissues that have
been studied in this report.
We observed significant allelic differences (p < 0.05)
for two of the seven SNPs in SW872 cells (rs118021693
and rs113120232; Fig. 3b) and for three of the seven
SNPs in U2OS cells (rs118021693, rs113120232 and
rs79866171; Fig. 3c). Two of these SNPs are common
between the two cell lines: rs118021693 and
rs113120232. As noted above, we analysed two regions
encompassing rs118021693 and it was the smaller of the
two (the “A” region) that showed an allelic effect in
SW872 and U2OS. Both allelic forms of rs118021693
showed reduced luciferase activity relative to the control
plasmid (pGL3 promoter, far right bar in Fig. 3b and c),
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Fig. 2 eQTL analysis of MCF2L in joint tissues. The individuals included
in the expression analysis of Fig. 1a were genotyped at rs11842874.
Gene expression, as measured by qPCR, was then stratified by
genotype at the SNP, with individuals placed into two genotypic
groups: AA homozygotes and G carriers (AG plus GG). The data is
presented as columnar scatter plots for each tissue type. Each data
point represents the mean of three technical repeats. Horizontal lines
represent the mean and standard error of the mean. Statistical
significance was assessed using the Mann–Whitney U test and is not
corrected for multiple testing
Table 1 Six SNPs in high (r2 > 0.8) linkage disequilibrium with
rs11842874
Pairwise linkage
disequilibrium
with rs11842874
SNP Alleles
(major/minor)
Minor allele
frequency
r2 D’
rs75351348 G/A 0.085 0.85 1
rs118021693 C/G 0.058 1 1
rs76623552 A/G 0.058 1 1
rs11842874 A/G 0.066 – –
rs1888227 T/C 0.050 1 1
rs113120232 C/T 0.067 0.867 1
rs79866171 C/G 0.058 1 1
For each SNP, the major and minor alleles, minor allele frequencies, and pairwise
r2 and D’ values are listed for the HapMap Central European population
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and in both cell lines the major C allele showed a greater
reduction in luciferase activity relative to the minor G
allele. Both allelic forms of the rs113120232 region
showed increased luciferase activity relative to the con-
trol plasmid, and this effect was greater for the minor T
allele relative to the major C allele in both cell lines.
In summary, this luciferase analysis demonstrated: 1)
that the region of intron 4 of MCF2L encompassing the
OA association signal has transcriptional regulatory
activity; 2) that three of the seven SNPs correlating with
the signal show statistically significant differential allelic
expression and; 3) that for two of these three SNPs, the
effects are observed in both cell types examined and in
the same allelic direction.
Discussion
We initially demonstrated the expression of MCF2L and
the presence of its protein product, DBS, in three major
tissues of the synovial joint; cartilage, synovial membrane
and infrapatellar fat pad. This analysis also highlighted
quantitative differences in the expression of the gene
between these tissues, as well as differences in relative
transcript isoform expression. We subsequently identified
a synovium tissue eQTL that operates on MCF2L and
which correlates with the 13 kb association signal marked
by SNP rs11842874. Finally, we uncovered allelic function-
ality at SNPs within the association interval, which is
located within intron 4 of the gene. Our study therefore
provides a potential mechanism through which the
rs11842874 signal acts as an OA susceptibility locus,
namely the modulation of MCF2L expression in syno-
vium tissue.
DBS is a guanine nucleotide exchange factor that has
not been investigated to a great degree. However, and as
noted in the Introduction, it is known to interact with
signalling proteins involved in chondrocyte development
and hypertrophy, and with proteins involved in the inva-
sive properties of fibroblast-like synoviocytes [8–15]. It
does therefore have a known role in joint tissue biology.
In our RNA-seq analysis we noted thatMCF2L expression
was higher in synovial macrophages in the presence of
TNF than in its absence. TNF and other proinflammatory
cytokines have a well-defined role in cartilage degradation
and OA synovitis [22] and this result may therefore indi-
cate that MCF2L is involved in this inflammatory pathway
in synovial macrophages.
Our discovery of an eQTL acting in synovium tissue
but apparently not in cartilage emphasises that OA is
not exclusively a cartilage disease but instead has joint-
wide effects. We have previously reported on synovium
tissue eQTLs in OA patients [16, 23, 24], but as far as
we are aware, this is the first example of one operating
in synovium tissue but not in cartilage. It is of course
possible that the eQTL is active in cartilage and that we
lacked the power to detect it, despite analysing the
cartilage of over 75 OA patients.
In the synovium tissue eQTL analysis, increased
expression of MCF2L correlated with the risk-conferring
A allele of rs11842874. This is the common allele of the
SNP. In the luciferase studies, the two SNPs that dem-
onstrated a consistent effect in both SW872 and U2OS
cells, rs118021693 and rs113120232, each showed
reduced expression of their common alleles relative to
their rare alleles. Due to the very high LD in the associ-
ation interval, the common alleles of rs118021693 and
rs113120232 are on the same haplotype as the common
allele of rs11842874. There is therefore a contradiction
between the results of the eQTL and the luciferase studies.
This can be accounted for by a number of differences
between the two experimental approaches. For ex-
ample: 1) the luciferase assays used liposarcoma and
osteosarcoma cells whereas the eQTL was observed
in synovial cells; 2) the luciferase assays used trans-
formed cells whereas the eQTL analysis used tissue
and; 3) in a luciferase assay, a linearised piece of
DNA is studied, which cannot realistically mimic the
chromatin interactions present in the cell in vivo. The
purpose of the luciferase assay was to assess whether
the two alleles of a SNP mediate differential gene
expression; if they do, this implies that the SNP has
the capacity to act as an eQTL. The luciferase assay
is therefore an in vitro test of SNP functionality
whereas the tissue-based eQTL analysis measured the
actual activity of the MCF2L gene in the synovium
tissue of patients at the time of their operation and
according to their rs11842874 genotype.
(See figure on previous page.)
Fig. 3 Functional analysis of SNPs within the rs11842874 linkage disequilibrium block. (a) Schematic diagram of the 7 SNPs within the LD block.
The SNPs are within an 11.4 kb region located within the MCF2L gene body (intron 3 relative to transcript isoforms 002 and 201); adapted from
the UCSC genome browser. Luciferase reporter analyses were performed in (b) SW872 liposarcoma and (c) U2OS osteosarcoma cells. Cells were
transfected with luciferase reporter constructs and a renilla reporter vector. Luciferase activity was quantified and normalised to renilla activity and
to the empty luciferase vector. Mean luciferase/renilla data is plotted, with error bars representing standard error of the mean from six technical
repeats and a minimum of six biological repeats. SNPs are presented in their physical order on the x-axis. Major (risk) alleles are presented as black
filled bars, minor alleles as grey filled bars. Two fragments encompassing rs118021693 were analysed; fragment A and the larger fragment B. Statistical
significance represents the difference between alleles for each SNP and was assessed using the Mann–Whitney U test, and is not corrected for multiple
testing. ns not-significant, *p < 0.05, **p < 0.01, ***p < 0.001
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Overall, we have described tissue-specific effects of
genotype at rs11842874 on MCF2L expression, which is
in agreement with recent studies suggesting that many
genetic variants associated with complex traits are likely
to affect gene expression through eQTLs in a tissue
specific manner [25]. Further functional analyses of the
SNPs within the association interval, of MCF2L and of
DBS are now justified to fully comprehend how this
13q34 locus increases OA susceptibility.
Conclusion
MCF2L is subject to a cis-acting eQTL in the synovial
membrane tissue of patients that correlates with the OA
association signal at this locus. This may therefore be
the mechanism through which this genetic suscepti-
bility is acting. Furthermore, there are predicted and
experimentally confirmed functional SNPs within the
association interval that correlate with the signal and
which show differential allelic expression. These now
merit further investigation as potential drivers of the
association signal.
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